Acute myeloid leukaemia (AML) Program in Pharmaceutical Benefits Scheme (PBS) 012-18120338

AML restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

$\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.png$ PBS AML restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Acute myeloid leukaemia - midostaurin - initial maintenance authority application form (PB253)

Acute myeloid leukaemia - oral azacitidine - dose escalation therapy continuing authority application form (PB355)

Services Australia website

Acute myeloid leukaemia

External websites

PBS schedule for:

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item	Description
1	Can an initial approval for midostaurin be done over the phone? Yes. Induction and consolidation are done by telephone or electronic approval. The prescriber then completes an initial maintenance application in writing or electronically.
2	Can a patient switch from azacitidine injection to tablets as continuing treatment? No. The injection and tablets have different PBS criteria. Patients must meet the initial PBS criteria for the tablets.
3	Can dose escalation for azacitidine 300mg tablet be approved by phone? No. The prescriber must request a higher quantity of this PBS listing in writing or electronically. This is the only listing for the tablets that has a PBS application form.
4	How is the quantity for daunorubicin+cytarabine entered in OPA? This is an efficient funding of chemotherapy (EFC) listing. The quantity is entered in OPA based on the dose, in milligrams, of daunorubicin that is required.